It claimed 'GLP-1s for diabetes could be sold at a profit for just US $0.89 per month, compared to the price of $95 per month charged in Brazil, $115 per month charged in South Africa, $230 charged in Latvia and $353 charged in the US, which is a 39,562% markup over what the estimated generic price could be.' Christa Cepuch, Pharmacist Coordinator at MSF's Access Campaign, argues 'These new drugs are an absolute game changer for people living with diabetes, but are being kept out of the hands of hundreds of millions of people in low- and middle-income countries who need them' (Barber, Gotham, Bygrave
Adeshirlarijaney, A., Zou, J., Tran, H
In comparative studies, Tirzepatide has shown a "GIP-heavy" bias, which many researchers suspect is the reason for its superior tolerability compared to high-dose GLP-1 monotherapies
The half-life of this hormone is only approximately two minutes, with cleavage by DPP-4 enzymes occurring at the second residue of incretins, resulting in only 1015% of secreted GLP-1 reaching the systemic circulation [26]
Tirzepatide is marketed as Zepbound for non-diabetic weight loss and Mounjaro for diabetes
The amplified AMPK effect is a theoretical concern that has not been formally characterized in humans